Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 4/20 | 0.58 |
| ▸ | MMP12 | P39900 | 1/20 | 0.55 |
| ▸ | QPCTL | Q9NXS2 | 3/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | QPCT | Q16769 | 6/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1875298 | 0.88 | P2RY14 (0.49) | P2RY14MMP12QPCTLP2RX3LTA4H | |
| SCHEMBL14547884 | 0.85 | MMP12 (0.55) | P2RY14MMP12QPCTLP2RX3QPCT | |
| SCHEMBL3154557 | 0.82 | P2RY14 (0.53) | P2RY14MMP12QPCTLQPCTPRKCI | |
| SCHEMBL29770425 | 0.81 | MMP12 (0.62) | MMP12QPCTLQPCTPRKCIKDM4E | |
| SCHEMBL1799380 | 0.81 | MMP12 (0.62) | MMP12QPCTLQPCTPRKCIKDM4E | |
| SCHEMBL23636200 | 0.80 | MMP12 (0.60) | P2RY14MMP12QPCTLP2RX3QPCT | |
| SCHEMBL30468011 | 0.80 | MMP12 (0.60) | P2RY14MMP12QPCTLP2RX3QPCT | |
| SCHEMBL30467970 | 0.80 | MMP12 (0.60) | MMP12QPCTLQPCTPRKCIKDM4E | |
| SCHEMBL23636201 | 0.80 | MMP12 (0.60) | MMP12QPCTLQPCTPRKCIKDM4E | |
| SCHEMBL7013293 | 0.80 | PRKCI (0.66) | MMP12QPCTLQPCTPRKCIKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939528-B2 | Heterocycle compounds | GLAXOSMITHKLINE LLC (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939528-B2 | Heterocycle compounds | GLAXOSMITHKLINE LLC (US) | 2011-05-10 | — | — | US | disclosed |
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-02-26 | — | — | US | disclosed |
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-02-26 | — | — | US | disclosed |
| WO-2007047397-A2 | PHENOL ETHERS AS MODULATORS OF THE OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | OPRK1, OPRL1, OPRD1 | P2RY14 470/4885MMP12 2506/4885QPCTL 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.